Ligand Pharmaceuticals, Inc. (LGND)
233.64
-1.69
(-0.72%)
USD |
NASDAQ |
May 27, 15:01
Ligand Pharmaceuticals Cash from Investing (Quarterly) : -94.35M for March 31, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| XOMA Royalty Corp. | 6.552M |
| Johnson & Johnson | -1.04B |
| Organon & Co. | 386.00M |
| Merck & Co., Inc. | -10.21B |
| Phathom Pharmaceuticals, Inc. | -0.061M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 48.69M |
| Cash from Financing (Quarterly) | -14.13M |
| Free Cash Flow | 114.06M |
| Free Cash Flow Per Share (Quarterly) | 2.437 |
| Free Cash Flow to Equity (Quarterly) | 47.98M |
| Free Cash Flow to Firm (Quarterly) | 49.42M |
| Free Cash Flow Yield | 2.39% |